Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 68

Sort by

Sort Order Select

Journal Articles

Transformation from Indolent Primary Cutaneous Marginal Zone Lymphoma to Aggressive Primary Cutaneous Diffuse Large B-Cell Lymphoma: A Rare Case and Review of the Literature

Emily Harris, Ariel Sindel, DO, Ian McConnell, William Clark, MDMS, Alden Chesney, MD, Victor Yazbeck, MD

Blood (2019) 134 (Supplement_1): 5266.

https://doi.org/10.1182/blood-2019-130921

Published: 2019

Journal Articles

Results of a Phase I/II Study of Bendamustine in Combination with Ofatumumab, Carboplatin and Etoposide (BOCE) for Relapsed or Refractory Aggressive B-Cell Non-Hodgkin Lymphomas

Jonathan Pan, MD, Sushil Ghimire, MD, Tingting Zhan, PhD, Onder Alpdogan, MD, Andrew E. Chapman, DO, Matthew Carabasi, MD, Ubaldo Martinez-Outschoorn, MD, Lewis J. Rose, MD, Michael Ramirez, MD, John L Wagner, MD, Barbara Pro, MD, Mark A. Weiss, MD, Neal Flomenberg, MD, Pierluigi Porcu, MD, Joanne Filicko-O'Hara, MD, Sameh Gaballa, MD

Blood (2019) 134 (Supplement_1): 5318.

https://doi.org/10.1182/blood-2019-125836

Published: 2019

Journal Articles

Real World Outcomes of Patients with Relapsed/Refractory Diffuse Large B Cell Lymphoma Who Are Ineligible for Autologous Stem Cell Transplantation and Receive Commercially-Available Salvage Therapy

Emily C. Ayers, MD, David J Margolis, MD, Phyllis A. Gimotty, PhD, Daniel J. Landsburg, MD

Blood (2019) 134 (Supplement_1): 2893.

https://doi.org/10.1182/blood-2019-128815

Published: 2019

Journal Articles

Utility of Daily Laboratories in Patients with Lymphoma Admitted for Inpatient Chemotherapy

Daniel Anscher, MD, Ahmad El-Far, MD, Said M Baidas

Blood (2019) 134 (Supplement_1): 3417.

https://doi.org/10.1182/blood-2019-121558

Published: 2019

Journal Articles

Interim Circulating Tumor DNA As a Prognostic Biomarker in the Setting of Interim PET-Based Adaptive Therapy for DLBCL

Charles Macaulay, MSc, BA, Stefan Alig, MD, David M. Kurtz, MD PhD, Michael C. Jin, BS, Stephen Opat, Joanne Soo, MD, Brian Sworder, MD PhD, Mark S. Hertzberg, MD PhD, Maher K. Gandhi, PhD, Maximilian Diehn, MD PhD, Ash A. Alizadeh, MD PhD

Blood (2019) 134 (Supplement_1): 1600.

https://doi.org/10.1182/blood-2019-131278

Published: 2019

Journal Articles

Event-Free Survival As a Surrogate for Overall Survival in Relapsed DLBCL after Autologous Transplant: A Subgroup Analysis of LY.12 and Coral

Sarit Assouline, MD, Shen Li, MD, Christian Gisselbrecht, MD, Patrick Fogarty, Annette E. Hay, Eric Van Den Neste, MD, Lois E. Shepherd, Norbert Schmitz, MD, Tara Baetz, Armand Keating, MD, Sue Robinson, MD, Matthew D. Seftel, FRCP,FRCPC,MPH,MD, Caterina Stelitano, Marina S. Djurfeldt, Ralph Meyer, Bingshu E. Chen, Michael Crump, MD FRCPC

Blood (2019) 134 (Supplement_1): 768.

https://doi.org/10.1182/blood-2019-124879

Published: 2019

Journal Articles

Parsaclisib, a potent and highly selective PI3Kδ inhibitor, in patients with relapsed or refractory B-cell malignancies

Andres Forero-Torres, Radhakrishnan Ramchandren, Abdulraheem Yacoub, Michael S. Wertheim, William J. Edenfield, Paolo Caimi, Martin Gutierrez, Luke Akard, Carolina Escobar, Justin Call, Daniel Persky, Swaminathan Iyer, Douglas J. DeMarini, Li Zhou, Xuejun Chen, Fitzroy Dawkins, Tycel J. Phillips

Blood (2019) 133 (16): 1742–1752.

https://doi.org/10.1182/blood-2018-08-867499

Published: 2019

Includes: Supplemental data

Journal Articles

Short Time between Progression after Immunochemotherapy and Initiation of Salvage Therapy (PTI) Is Associated with Inferior Long-Term Outcomes in Patients with Relapsed/Refractory DLBCL

Matthew J. Maurer, MS, Umar Farooq, MD, Madison M Wahlen, Thomas M. Habermann, MD, Gita Thanarajasingam, MD, Sergei Syrbu, MD PhD, William R. Macon, MD, Patrick Johnston, MD, Ivana Micallef, MD, Luis Porrata, MD, Susan L. Slager, PhD, Stephen M. Ansell, MD PhD, Thomas E. Witzig, MD, James R. Cerhan, MD PhD, Grzegorz S. Nowakowski, MD, Carrie A. Thompson, MD, Brian K. Link, MD

Blood (2018) 132 (Supplement 1): 4204.

https://doi.org/10.1182/blood-2018-99-114331

Published: 2018

Journal Articles

Outcome of Patients with Aggressive B Cell Lymphomas Who Receive Second-Line Salvage Immunochemotherapy Following Treatment Failure of Intensive First-Line Immunochemotherapy

Emily C. Ayers, MD, Shaoying Li, MD, Jeffrey Medeiros, MD, David A. Bond, MD, Kami J. Maddocks, MD, Pallawi Torka, MD, Angel Mier Hicks, MD, Madeira Curry, Nina D. Wagner-Johnston, MD, Reem Karmali, MD, Amir Behdad, MD, Bita Fakhri, MDMPH, Brad S Kahl, MD, Michael C Churnetski, BS, Jonathon B. Cohen, MDMS, Nishitha Reddy, MD, Dipenkumar Modi, MD, Radhakrishnan Ramchandren, MD, Christina Howlett, PharmD, BCOP, Lori A. Leslie, MD, Samuel Cytryn, Catherine Diefenbach, MD, Rawan Faramand, MD, Julio C. Chavez, MD, Adam J Olszewski, MD, Yang Liu, MD, Stefan Klaus Barta, MDMRCP,MS, Dhruvika Mukhija, MD, Brian T. Hill, MD PhD, Helen Ma, MD, Jennifer E Amengual, MD, Sunita Nathan, MD, Sarit Assouline, Victor M. Orellana-Noia, MD, Craig A. Portell, MD, Ashwin Chandar, MD, Kevin A. David, MD, Anshu Giri, MD, Brian T. Hess, MD, Daniel J. Landsburg, MD

Blood (2018) 132 (Supplement 1): 453.

https://doi.org/10.1182/blood-2018-99-115527

Published: 2018

Journal Articles

Efficacy of Rituximab Maintenance for Diffuse Large B Cell Lymphoma with Transformation

Hideki Uryu, MD, Yuko Mishima, MD PhD, Masahiro Yokoyama, MD, Noriko Nishimura, MD PhD, Yoshiharu Kusano, MD, Norihito Inoue, MD, Anna Nishihara, MD, Takanori Fukuta, MD, Yuko Shirouchi, MD, Naoko Tsuyama, MD PhD, Kengo Takeuchi, MD PhD, Yasuhito Terui, MD PhD

Blood (2018) 132 (Supplement 1): 4229.

https://doi.org/10.1182/blood-2018-99-111513

Published: 2018

Journal Articles

Safety and Efficacy of Venetoclax Combined with Rituximab, Ifosfamide, Carboplatin and Etoposide Chemoimmunotherapy (VICER) for Treatment of Relapsed Diffuse Large B Cell Lymphoma: Results from the Phase 1 Study

Paolo Caimi, MD, Deepa Jagadeesh, MDMPH, Kirsten Marie Boughan, DO, Robert M. Dean, MD, Brenda Cooper, MD, Brad Pohlman, MD, Molly M Gallogly, MDPhD, Sarah L. Ondrejka, DO, Erika Moore, MD, Kwadwo Asare Oduro, MDPhD, Eric D. Hsi, MD, Marcos de Lima, MD, Brian T. Hill, MD PhD

Blood (2018) 132 (Supplement 1): 397.

https://doi.org/10.1182/blood-2018-99-115587

Published: 2018

Journal Articles

Cost Consideration of Second Line Therapy for Relapsed Diffuse Large Lymphoma in the Community Setting

Danny Landau, MD, Brandon Wilds, PharmD, Sammy Mouslly

Blood (2018) 132 (Supplement 1): 5854.

https://doi.org/10.1182/blood-2018-99-111176

Published: 2018

Journal Articles

Ibrutinib Monotherapy in Patients with Relapsed or Refractory Chronic Lymphocytic Leukemia or Mantle Cell Lymphoma: A Retrospective Single Center Experience from India

Rayaz Ahmed, MDDM, Dinesh Bhurani, MD DM, FRCPA, Narendra Agarwal, MD DM, Jyotsna Kapoor, MSc, Neha Gurha, MD, Manan Shah, MBBS, MHA, Prashant Narang, MD

Blood (2018) 132 (Supplement 1): 5561.

https://doi.org/10.1182/blood-2018-99-112348

Published: 2018

Journal Articles

Safety of Autologous Stem Cell Transplantation in Patients with Known HTLV-1 Infection: A Case Series of 4 Patients

Vishal K Gupta, MD, Paul White, MD, Vaishali Sanchorawala, MD, Karen Quillen, MD MPH, Shayna Sarosiek, MD, Dina Brauneis, NP, John Mark Sloan, MD

Blood (2018) 132 (Supplement 1): 5738.

https://doi.org/10.1182/blood-2018-99-110230

Published: 2018

Journal Articles

Improving on R-ICE in relapsed DLBCL

Sarit Assouline

Blood (2018) 131 (16): 1767–1768.

https://doi.org/10.1182/blood-2018-02-832147

Published: 2018

Journal Articles

A phase 1 study of ibrutinib in combination with R-ICE in patients with relapsed or primary refractory DLBCL

Craig S. Sauter, Matthew J. Matasar, Heiko Schoder, Sean M. Devlin, Pamela Drullinsky, John Gerecitano, Anita Kumar, Ariela Noy, Maria L. Palomba, Carol S. Portlock, David J. Straus, Andrew D. Zelenetz, Susan J. McCall, Shoshana T. Miller, Amanda I. Courtien, Anas Younes, Craig H. Moskowitz

Blood (2018) 131 (16): 1805–1808.

https://doi.org/10.1182/blood-2017-08-802561

Published: 2018

Includes: Supplemental data

Journal Articles

Multicenter Retrospective Study of Features and Outcomes of Patients with Intravascular DLBCL Treated at Academic Institutions within the United States

Blood (2017) 130 (Supplement 1): 377.

https://doi.org/10.1182/blood.V130.Suppl_1.377.377

Published: 2017

Journal Articles

Efficacy of Salvage Chemotherapy in Diffuse Large B Cell Lymphoma with Primary Treatment Failure According to Putative Cell of Origin

Blood (2017) 130 (Supplement 1): 4141.

https://doi.org/10.1182/blood.V130.Suppl_1.4141.4141

Published: 2017

Journal Articles

Improved Outcome of Newly Diagnosed Childhood Mature B-Cell Lymphoma/Leukemia with High Tumor Burden Treated with BFM95-Based Protocol Combining Rituximab: A Report from Shanghai, China

Yang Fu, MBBS, Hongsheng Wang, MD, Xiaowen Zhai, MD PhD, Xiaowen Qian, MD, Jianhua Meng, MD, Hui Miao, MD, Xiaohua Zhu, MD PhD, Yi Yu, MD, Fengjuan Lu, MD

Blood (2017) 130 (Supplement 1): 4162.

https://doi.org/10.1182/blood.V130.Suppl_1.4162.4162

Published: 2017

Journal Articles

A Phase 1/2 Study of Carfilzomib Combined with Rituximab, Ifosfamide, Carboplatin and Etoposide (C-RICE) in Patients with Transplant-Eligible, Relapsed or Refractory (R/R) Diffuse Large B-Cell Lymphoma (DLBCL)

Pallawi Torka, MD, Seema Bhat, Kelvin P. Lee, MD, Alan Hutson, Jenna Nichols, Angela Kader, Cory Mavis, MSc, AnneMarie W Block, Sheila N. J. Sait, PhD, Bora E Baysal, MD PhD, Fadi Habib, MD, Vishala T. Neppalli, MD, Francisco J. Hernandez-Ilizaliturri, MD

Blood (2017) 130 (Supplement 1): 2822.

https://doi.org/10.1182/blood.V130.Suppl_1.2822.2822

Published: 2017

NARROW

Transformation from Indolent Primary Cutaneous Marginal Zone Lymphoma to Aggressive Primary Cutaneous Diffuse Large B-Cell Lymphoma: A Rare Case and Review of the Literature

Results of a Phase I/II Study of Bendamustine in Combination with Ofatumumab, Carboplatin and Etoposide (BOCE) for Relapsed or Refractory Aggressive B-Cell Non-Hodgkin Lymphomas

Real World Outcomes of Patients with Relapsed/Refractory Diffuse Large B Cell Lymphoma Who Are Ineligible for Autologous Stem Cell Transplantation and Receive Commercially-Available Salvage Therapy

Utility of Daily Laboratories in Patients with Lymphoma Admitted for Inpatient Chemotherapy

Interim Circulating Tumor DNA As a Prognostic Biomarker in the Setting of Interim PET-Based Adaptive Therapy for DLBCL

Event-Free Survival As a Surrogate for Overall Survival in Relapsed DLBCL after Autologous Transplant: A Subgroup Analysis of LY.12 and Coral

Parsaclisib, a potent and highly selective PI3Kδ inhibitor, in patients with relapsed or refractory B-cell malignancies

Short Time between Progression after Immunochemotherapy and Initiation of Salvage Therapy (PTI) Is Associated with Inferior Long-Term Outcomes in Patients with Relapsed/Refractory DLBCL

Outcome of Patients with Aggressive B Cell Lymphomas Who Receive Second-Line Salvage Immunochemotherapy Following Treatment Failure of Intensive First-Line Immunochemotherapy

Efficacy of Rituximab Maintenance for Diffuse Large B Cell Lymphoma with Transformation

Safety and Efficacy of Venetoclax Combined with Rituximab, Ifosfamide, Carboplatin and Etoposide Chemoimmunotherapy (VICER) for Treatment of Relapsed Diffuse Large B Cell Lymphoma: Results from the Phase 1 Study

Cost Consideration of Second Line Therapy for Relapsed Diffuse Large Lymphoma in the Community Setting

Ibrutinib Monotherapy in Patients with Relapsed or Refractory Chronic Lymphocytic Leukemia or Mantle Cell Lymphoma: A Retrospective Single Center Experience from India

Safety of Autologous Stem Cell Transplantation in Patients with Known HTLV-1 Infection: A Case Series of 4 Patients

Improving on R-ICE in relapsed DLBCL

A phase 1 study of ibrutinib in combination with R-ICE in patients with relapsed or primary refractory DLBCL

Multicenter Retrospective Study of Features and Outcomes of Patients with Intravascular DLBCL Treated at Academic Institutions within the United States

Efficacy of Salvage Chemotherapy in Diffuse Large B Cell Lymphoma with Primary Treatment Failure According to Putative Cell of Origin

Improved Outcome of Newly Diagnosed Childhood Mature B-Cell Lymphoma/Leukemia with High Tumor Burden Treated with BFM95-Based Protocol Combining Rituximab: A Report from Shanghai, China

A Phase 1/2 Study of Carfilzomib Combined with Rituximab, Ifosfamide, Carboplatin and Etoposide (C-RICE) in Patients with Transplant-Eligible, Relapsed or Refractory (R/R) Diffuse Large B-Cell Lymphoma (DLBCL)

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only